The U.S. Food and Drug Administration (FDA) has announced plans to remove the boxed warnings from menopausal hormone therapies (MHTs), also known as hormone replacement therapies (HRTs), marking a significant shift in women’s healthcare policy. The decision follows recommendations from an expert advisory panel convened in July 2025 and reflects a broader reassessment of long-standing concerns about hormone therapy safety.
A Shift in Perspective for Women’s Health
Menopausal hormone therapies are prescribed to alleviate symptoms such as hot flashes, night sweats, and vaginal dryness, as well as to help prevent osteoporosis in postmenopausal women. In 2002, the Women’s Health Initiative (WHI) published a study linking HRT use to increased risks of cardiovascular disease and breast cancer, prompting the FDA to issue black box warnings—the most serious type of safety alert.
However, new evidence and expert analysis suggest that the 2002 study overstated the risks and failed to reflect the broader population of HRT users. During a press conference, FDA Commissioner Marty Makary emphasized that the earlier interpretation of the data “tragically denied tens of millions of women the long-term health benefits of hormone replacement therapy.”
Health and Human Services Secretary Robert Kennedy Jr. echoed this sentiment, stating that the decline in HRT use following the WHI study “was not progress—it was neglect.” Before 2002, approximately one in four women used hormone therapy; after the study, the number fell to fewer than one in twenty.
What’s Changing
Under the FDA’s new approach, several long-standing warnings will be removed or revised:
- Elimination of boxed warnings referencing cardiovascular disease, breast cancer, and probable dementia.
- Removal of endometrial cancer warnings from combination hormone therapies (but retained for estrogen-only products).
- Elimination of recommendations to use “the lowest effective dose for the shortest duration.”
- Updated guidance suggesting treatment initiation for moderate to severe night sweats in women under 60 or within ten years of menopause onset.
For local vaginal estrogen therapies, the FDA will condense and simplify safety labeling, focusing on information most relevant to local formulations.
During the announcement, urologist Dr. Kelly Kasperson described the change as “a monumental shift in women’s health,” noting that it corrects decades of overly cautious guidance based on outdated science.
New Options for Patients
In conjunction with the labeling updates, the FDA also approved two new medications for menopause management:
- A generic version of Premarin, marking the first hormone replacement therapy generic approval in more than 30 years.
- A non-hormonal therapy for hot flashes, expanding treatment options for women who cannot or prefer not to use hormone-based products.
These approvals reflect the agency’s renewed focus on evidence-based medicine and patient-centered care, providing more personalized choices for symptom management.
A Modern Approach to Risk and Regulation
The FDA’s decision highlights the importance of continuously revisiting medical guidance as science evolves. By removing outdated warnings and aligning labeling with current data, the agency aims to restore confidence in hormone therapy as a safe, effective treatment option when prescribed appropriately.
This policy shift also demonstrates the FDA’s broader movement toward risk-based regulation, ensuring that labeling reflects real-world data and fosters informed decision-making between patients and providers.
At EMMA International
At EMMA International, we help life-science organizations navigate the evolving regulatory landscape with confidence. From labeling compliance and risk-based quality management to FDA submission strategy and post-market surveillance, our team ensures that products remain safe, effective, and aligned with current regulatory expectations.
As the FDA continues to modernize its approach to drug labeling and risk communication, EMMA International supports clients in adapting their regulatory strategies to maintain compliance and trust.
For more information on how EMMA International can assist, visit www.emmainternational.com or contact us at (248) 987-4497 or info@emmainternational.com.
Reference:
Eglovitch, J. (2025, November 10). FDA to remove boxed warnings from hormone therapies for menopause. Regulatory Focus, Regulatory Affairs Professionals Society.
U.S. Food and Drug Administration. (2025). FDA Announcement on Labeling Changes for Menopausal Hormone Therapy Products.
